# Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

> **NCT03922724** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 330 (estimated)

## Conditions studied

- Peripheral T-cell Lymphomas
- Lymphoproliferative Disorders
- Immune System Diseases

## Interventions

- **DRUG:** ATL-RIC
- **DRUG:** mRIC
- **PROCEDURE:** allo HCT
- **DRUG:** RIC
- **DRUG:** GVHD prophylaxis
- **DRUG:** IOC

## Key facts

- **NCT ID:** NCT03922724
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-04-18
- **Primary completion:** 2026-10-31
- **Final completion:** 2030-10-31
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03922724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03922724, "Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03922724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*